Syndax Pharmaceuticals Collaborates with Genentech to examine entinostat

Syndax Pharmaceuticals that is developing entinostat and SNDX-6352 in multiple cancer indications declared collaboration with a member of Roche Group, Genentech to evaluate  the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer.

Briggs W. Morrison, M.D., Chief Executive Officer of Syndax stated “While checkpoint inhibitors have shown initial promise in triple-negative breast cancer, there is a clear need to augment the effectiveness of such therapies in the setting of HR+, HER2- breast cancer.”

Phase Ib/II, open-label, multicenter, randomized trial will enroll patients with metastatic HR+, HER2- breast cancer who have experienced disease progression during or following first-line therapy. Genentech will be responsible for conducting the trial. ENCORE 602 is set to complete enrollment in the Phase II portion of the trial in the first half of 2018 having announced a separate collaboration with Genentech for ENDCORE 602.